

# Resuscitation-Promoting Factors Are Required for $\beta$ -Lactam Tolerance and the Permeability Barrier in *Mycobacterium tuberculosis*

Carl N. Wivagg<sup>a</sup> and Deborah T. Hung<sup>a,b,c</sup>

Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, USA<sup>a</sup>; Infectious Disease Initiative, Broad Institute, Cambridge, Massachusetts, USA<sup>b</sup>; and Department of Molecular Biology and Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts, USA<sup>c</sup>

**Mycobacterial resuscitation-promoting factors (RPFs) have been of great interest since the discovery that they promote the growth of nonculturable *Mycobacterium tuberculosis* cells. Yet, their precise role in mycobacterial survival and infection has remained elusive. We performed a chemical screen to identify molecules that show preferential killing of a *Mycobacterium tuberculosis* mutant lacking RPFs over wild-type bacilli and found that the mutant has enhanced sensitivity to the  $\beta$ -lactam class of antibiotics. By monitoring  $\beta$ -lactam diffusion across the mycobacterial outer membrane, we found that the RPFs are required to maintain the outer membrane integrity, as their deletion results in an increase in outer membrane permeability.**

*Mycobacterium tuberculosis*, the causative agent of tuberculosis, resists killing by many antibiotics. This resistance arises partly from the unique mycobacterial long-chain mycolic acids that are covalently bound to the cell wall peptidoglycan by intermediate arabinogalactan polymers, encasing the bacterium in a poorly permeable, hydrophobic shell. Bacteria regulate growth and division using many classes of peptidoglycan-modifying enzymes to remodel the cell wall, including, in *M. tuberculosis*, the five resuscitation-promoting factors (RPFs; *rpfA* to *-E*), which are thought to correspond to peptidoglycan lytic transglycosylases in Gram-negative organisms. Like lytic transglycosylases, RPFs are not essential for *in vitro* growth. Thus, deletion of all five RPF homologues (H37Rv $\Delta$ *rpfACDEB*, here RPF<sup>null</sup>) in *M. tuberculosis* has no effect on bacterial viability in broth culture, although on solid agar delayed colony formation has been observed (5). In contrast, the RPFs are essential for growth and persistence in a mouse model of *M. tuberculosis* infection (5). Since cell wall growth and division can apparently proceed *in vitro* in the absence of RPFs, it is unclear what their essential role is *in vivo*.

Homology studies, demonstrated enzymatic activity (8), and interactions with other cell wall-modifying enzymes (3) all suggest that RPFs can function to modify peptidoglycan. Because of the covalent interaction between the peptidoglycan and the mycolic acids, alterations to peptidoglycan may affect the outer membrane, the integrity of which contributes to hallmark mycobacterial characteristics, including clumping of cells in culture, impermeability, and broad antibiotic tolerance. RPFs may therefore contribute to these characteristics.

In order to elucidate further roles of the RPFs in *M. tuberculosis*, we performed a high-throughput chemical screen of 26,000 compounds to identify molecules that preferentially inhibit growth of an *M. tuberculosis* mutant in which all 5 *rpf* genes have been deleted (RPF<sup>null</sup>) but not wild-type *M. tuberculosis* (RPF<sup>WT</sup>). RPF<sup>null</sup>, a generous gift of V. Mizrahi (University of the Witwatersrand, Johannesburg, South Africa), was engineered to constitutively express red fluorescent protein and grown to logarithmic phase in Middlebrook 7H9 broth, centrifuged at 58  $\times$  g to remove large clumps, diluted to an optical density at 600 nm (OD<sub>600</sub>) of 0.05 in fresh medium, and dispensed into 384-well plates containing dimethyl sulfoxide (DMSO) stocks of individual small mole-

cules (final concentration,  $\sim$ 25  $\mu$ M). The library (collection at the Broad Institute) contained known bioactive compounds, natural products, and synthetic compounds. After incubating for 4 days, outgrowth was determined by measuring fluorescence at an excitation wavelength of 544 nm and a detection cutoff of 580 nm.

We compared the results from this screen to a parallel screen against RPF<sup>WT</sup> and selected for follow-up the top 210 compounds for which there was a significant difference in Z score between RPF<sup>WT</sup> and RPF<sup>null</sup>. Of these, 147 (70%) had repeatable activity and were carried on for further analysis. Some compounds with significant differences in activity against the two strains may not have been identified because the screening concentration exceeded the inhibitory concentration of both strains. Compounds with general cytotoxicity in an erythrocyte lysis assay were eliminated.

We measured the 90% inhibitory concentration (IC<sub>90</sub>) of each compound for the RPF<sup>null</sup> and RPF<sup>WT</sup> strains by OD<sub>600</sub>. We also verified each compound's activity against an alternatively derived RPF<sup>null</sup> strain, H37Rv $\Delta$ *rpfACDEB*, in which all five RPF genes had been genetically knocked out in a different sequence. This ensured that each compound's activity was not associated with any non-RPF-related mutations acquired during the construction of the RPF deletion strains. We focused on 11 compounds (Table 1) with the most dramatic differences in activity against RPF<sup>null</sup> compared to the RPF<sup>WT</sup>. Of the 11 lead compounds, five were  $\beta$ -lactams, with four being cephalosporins (cefotaxime, cefditoren, ceftriaxone, and cefmetazole) and a fifth being a penicillin (dicloxacillin). We found that the IC<sub>90</sub> for RPF<sup>null</sup> against cefotaxime was  $\sim$ 8-fold lower than in RPF<sup>WT</sup> (Table 2), consistent with our screening results. We observed similar sensitizations of the mutant for ceftriaxone and cefamandole. CFU measurement for RPF<sup>WT</sup> and

Received 28 October 2011 Returned for modification 17 November 2011

Accepted 2 December 2011












Published ahead of print 12 December 2011

Address correspondence to Deborah T. Hung, hung@molbio.mgh.harvard.edu.

Copyright © 2012, American Society for Microbiology. All Rights Reserved.

doi:10.1128/AAC.06027-11

TABLE 1 Additional hits from RPF<sup>null</sup> screen

Compound structure	ChemBank <sup>a</sup> ID	Compound structure	ChemBank <sup>a</sup> ID
	1534811		3616095
	3060388		
	1265		3614409
	3078460		
	1067		3614391
	3173210		
	3614381		3553155

<sup>a</sup> ChemBank is a public cheminformatics resource available at <http://chembank.broad.harvard.edu/> (7).

TABLE 2 IC<sub>90</sub>s of  $\beta$ -lactams against H37Rv, RPF<sup>null</sup>, and related strains

$\beta$ -Lactam	Strain <sup>a</sup>	IC <sub>90</sub> ( $\mu$ M) <sup>b</sup>
Cefotaxime	H37Rv (RPF <sup>WT</sup> )	26
	H37Rv $\Delta$ <i>rfpA</i>	13–26
	H37Rv $\Delta$ <i>rfpB</i>	13–26
	H37Rv $\Delta$ <i>rfpC</i>	26
	H37Rv $\Delta$ <i>rfpD</i>	26
	H37Rv $\Delta$ <i>rfpE</i>	26–52
	H37Rv $\Delta$ <i>rfpAB</i>	26
	H37Rv $\Delta$ <i>rfpACBED::pHrfpCDE</i>	6.5–26
	H37Rv $\Delta$ <i>rfpACBE</i>	6.5
	H37Rv $\Delta$ <i>rfpACBED</i> (RPF <sup>null</sup> )	1.6–3.3
H37Rv $\Delta$ <i>rfpACDEB</i> <sup>c</sup>	0.78	
Cefamandole	H37Rv (RPF <sup>WT</sup> )	390–780
	H37Rv $\Delta$ <i>rfpACBED</i> (RPF <sup>null</sup> )	98
	With potassium clavulanate (1 $\mu$ M)	
H37Rv (RPF <sup>WT</sup> )	24	
H37Rv $\Delta$ <i>rfpACBED</i> (RPF <sup>null</sup> )	1.5	
Ceftriaxone	H37Rv (RPF <sup>WT</sup> )	3.2–6.3
	H37Rv $\Delta$ <i>rfpACBED</i> (RPF <sup>null</sup> )	1.6

<sup>a</sup> From reference 5.

<sup>b</sup> Differences in IC<sub>90</sub>s are representative of at least two independent experiments containing at least four duplicates each; for cefamandole, amounts of clavulanate were varied across duplicates.

<sup>c</sup> RPFs were deleted from this strain in a different order than that for RPF<sup>null</sup>.

RPF<sup>null</sup> verified that observed effects on OD<sub>600</sub> arose from bactericidal activity (Fig. 1).

To determine which RPFs contributed to RPF<sup>null</sup>'s increased  $\beta$ -lactam sensitivity, we measured the cefotaxime IC<sub>90</sub> against a range of mutants lacking one or more RPFs (Table 2). No individual RPF gene was singlehandedly responsible for RPF<sup>WT</sup>-level cefotaxime resistance. The biggest increases in sensitivity came with the loss of *rfpA* and *rfpB*. In general, with the progressive loss of RPFs, cefotaxime sensitivity gradually increased. The additive effects observed suggest functional redundancy of the RPFs. Restoration of *rfpC*, *rfpD*, and *rfpE* by integration of a plasmid carrying these genes at the mycobacteriophage L5 *attB* site suppressed cefotaxime sensitivity in RPF<sup>null</sup>.

To test whether increased  $\beta$ -lactam sensitivity in RPF<sup>null</sup> could be due to loss of  $\beta$ -lactamase activity with sequential deletion of the RPFs, we measured the cefamandole IC<sub>90</sub> of RPF<sup>WT</sup> and RPF<sup>null</sup> in the presence of 1  $\mu$ M clavulanate, a  $\beta$ -lactamase inhibitor. If differences in  $\beta$ -lactamase activity account for the differ-




FIG 1 RPF<sup>WT</sup> and RPF<sup>null</sup> were grown in 3  $\mu$ M cefotaxime, and surviving bacteria were enumerated at the indicated time points by plating for CFU on 7H10 agar. The result shown is representative of the experiment performed in biological triplicate.




FIG 2 Kinetics of cefamandole hydrolysis. Absorption at 285 nm of H37Rv (●) or H37Rv $\Delta$ *rfpACBED* (■). Samples were mechanically lysed (A) or resuspended in phosphate-buffered saline intact (B) and exposed to 20 mM cefamandole nafate. Subsequently, absorption measurements were taken at the indicated times. The illustrated values are averages of two technical replicates for each strain. Parameters  $v_{lysed}$  and  $v_{intact}$  are the slope and error calculated from the aggregated data for each strain.

ences in cephalosporin sensitivity in the two strains, its inhibition by clavulanate should cause the cefamandole IC<sub>90</sub> values for the RPF<sup>WT</sup> and RPF<sup>null</sup> to converge. In fact, treatment with clavulanate did not cause this convergence; instead, a small divergence was observed (Table 2), thus demonstrating that loss of  $\beta$ -lactamase activity does not account for the increased  $\beta$ -lactam sensitivity in RPF<sup>null</sup>.

Since RPF<sup>null</sup> is also hypersensitive to SDS and macrolide antibiotics relative to RPF<sup>WT</sup> (5), we hypothesized that it may have a general permeability defect underlying both these phenotypes as well as cephalosporin sensitivity. To test this, using previously reported methods (9), we measured the relative rates of cefamandole hydrolysis by intact RPF<sup>WT</sup> and RPF<sup>null</sup> cells (Fig. 2). When these rates are normalized to their respective rate of hydrolysis in lysates, they provide a comparison of the relative rates of diffusion across the intact outer membrane and of their relative permeabilities (provided that the concentration of cefamandole internal to the permeability barrier is below the order of the  $\beta$ -lactamase  $K_m$ ). In highly permeable cells, intracellular hydrolysis of cefamandole is assumed to be rate determining, while in poorly permeable cells, diffusion through the permeability barrier is assumed to be rate limiting.

We calculated a  $v_{intact}/v_{lysed}$  ratio of  $1.09 \pm 0.04$  for RPF<sup>null</sup>, compared to an RPF<sup>WT</sup>  $v_{intact}/v_{lysed}$  ratio of  $0.07 \pm 0.09$ . We also found that the loss of cefamandole sensitivity observed with the

restoration of *rpfC*, *rpfD*, and *rpfE* in RPF<sup>null</sup> was reflected in a correspondingly lower  $v_{\text{intact}}/v_{\text{lysed}}$  ratio of  $0.19 \pm 0.04$ , indicative of decreased permeability. These results show that RPF<sup>null</sup> has increased permeability to cefamandole.

We have found that the deletion of RPFs in the *M. tuberculosis* H37Rv strain results in increased sensitivity to cephalosporins because of a resulting increased permeability in its outer membrane. While this work provides a clear demonstration of the change in permeability with respect to cephalosporins, it is possible that the reported sensitivity of RPF<sup>null</sup> to other small molecules, including SDS (5), the macrolide class of antibiotics, vancomycin, and rifampin (6), may also be due to this same permeability defect. This finding suggests that changes in mycobacterial cell physiology at the peptidoglycan level may have far-reaching effects on the essential mycolic acid permeability barrier and that such alterations may affect the ability of the mutant bacilli to survive *in vivo*. Specifically, loss of particular cell wall-modifying enzymes may decouple the rates of peptidoglycan and outer membrane synthesis, as suggested in a model by Heidrich et al. (2), thus causing defects in the outer membrane that permit a wide range of molecules to diffuse in and out of the cell.

Our work shows that genetic ablation of RPF activity can potentiate a number of small molecules against mycobacteria, including known antibiotics presently unused in therapy. The use of RPF inhibitors should have similar effects. Recently, Demina et al. (1) have identified several small molecules with promising RPF-inhibitory activity, while more generally bulgecin is a known inhibitor of lytic transglycosylases.  $\beta$ -Lactams are historically one of the most successful antibiotic classes, and the use of the  $\beta$ -lactamase inhibitor clavulanate to potentiate them against mycobacteria has recently been proposed (4). This work provides a

mechanistically orthogonal approach to potentiating  $\beta$ -lactam antibiotics and other antibiotics.

#### ACKNOWLEDGMENTS

We thank the members of the Hung lab for their helpful comments. We thank B. Gordhan, B. Kana, and V. Mizrahi (University of the Witwatersrand, Johannesburg, South Africa) for their generous gift of the strains and plasmid used in this work. We thank the Broad Institute Chemical Biology Platform for their assistance in performing the chemical screen.

#### REFERENCES

1. Demina GR, et al. 2009. Finding of low molecular weight inhibitors of resuscitation promoting factor enzymatic and resuscitation activity. *PLoS One* 4:e8174.
2. Heidrich C, Ursinus A, Berger J, Schwarz H, Höltje J. 2002. Effects of multiple deletions of murein hydrolases on viability, septum cleavage, and sensitivity to large toxic molecules in *Escherichia coli*. *J. Bacteriol.* 184:6093–6099.
3. Hett EC, et al. 2007. A partner for the resuscitation-promoting factors of *Mycobacterium tuberculosis*. *Mol. Microbiol.* 66:658–668.
4. Hugonnet J, Tremblay LW, Boshoff HI, Barry CE, Blanchard JS. 2009. Meropenem-clavulanate is effective against extensively drug-resistant *Mycobacterium tuberculosis*. *Science* 323:1215–1218.
5. Kana BD, et al. 2008. The resuscitation-promoting factors of *Mycobacterium tuberculosis* are required for virulence and resuscitation from dormancy but are collectively dispensable for growth *in vitro*. *Mol. Microbiol.* 67:672–684.
6. Kana BD, Mizrahi V, Gordhan BG. 2010. Depletion of resuscitation-promoting factors has limited impact on the drug susceptibility of *Mycobacterium tuberculosis*. *J. Antimicrob. Chemother.* 65:1583–1585.
7. Seiler KP, et al. 2008. ChemBank: a small-molecule screening and cheminformatics resource database. *Nucleic Acids Res.* 36:D351–D359.
8. Telkov MV, et al. 2006. Proteins of the *rpf* (resuscitation-promoting factor) family are peptidoglycan hydrolases. *Biochemistry (Mosc.)* 71:414–422.
9. Zimmermann W, Rosselet A. 1977. Function of the outer membrane of *Escherichia coli* as a permeability barrier to  $\beta$ -lactam antibiotics. *Antimicrob. Agents Chemother.* 12:368–372.